Consumer advocates warned Wednesday that pharmaceutical giant Moderna is \u0022taking taxpayers for a ride\u0022 after the company announced plans to charge between $32 and $37 per dose for a potential Covid-19 vaccine developed entirely with funds from the U.S. federal government.\u0022Taxpayers are paying for 100% of Moderna\u0026#039;s Covid-19 vaccine development. All of it,\u0022 Peter Maybarduk, director of the Access to Medicines Program at Public Citizen, said in a statement. \u0022Yet taxpayers may wind up paying tens of billions more to Moderna to buy our vaccine back, if it proves safe and effective.\u0022\u0022Taxpayers are paying for 100% of Moderna\u0026#039;s Covid-19 vaccine development. All of it. Yet taxpayers may wind up paying tens of billions more to Moderna to buy our vaccine back.\u0022 —Peter Maybarduk, Public Citizen\u0022The so-called Moderna vaccine belongs in significant part to the people of the U.S,\u0022 said Maybarduk. \u0022We paid for it. Federal scientists led the way. It ought to be the people\u0026#039;s vaccine, not a new taxpayer burden.\u0022The experimental vaccine is currently undergoing a Phase 3 clinical trial that is expected to enroll around 30,000 adult volunteers who do not have Covid-19, according to the National Institutes of Health (NIH). Trial results are expected as early as October.\u0022Results from early-stage clinical testing indicate the investigational mRNA-1273 vaccine is safe and immunogenic, supporting the initiation of a Phase 3 clinical trial,\u0022 Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said in a statement last week.For context, the $32-$37/dose Moderna cites for smaller volume agreements of #COVID19 vaccine is 60% more (on low end) than Pfizer price of $19.95/dose agreement with U.S. govt.Moderna notes price would be lower for larger volume agreements.Price would go up after pandemic. https://t.co/eki26YgK07— Meg Tirrell (@megtirrell) August 5, 2020Under pressure from advocacy groups to publicly disclose how its potential vaccine is being financed, Moderna told Axios Wednesday that U.S. taxpayers are providing \u0022100% funding of the program.\u0022Since April, the Massachusetts-based pharmaceutical company has received nearly a billion dollars in taxpayer grants to develop a vaccine as part of the Trump administration\u0026#039;s so-called Operation Warp Speed.\u0022The company received $483 million from the Biomedical Advanced Research and Development Authority in April to support its vaccine development,\u0022 CNBC reported. \u0022Last month, it announced it received an additional $472 million from the U.S. government.\u0022Dean Baker, senior economist at the Center for Economic and Policy Research, wrote in a blog post Wednesday that \u0022this funding paid for the research and testing\u0022 and \u0022it also meant that the government took all the risk.\u0022\u0022If Moderna\u0026#039;s vaccine turns out to be ineffective,\u0022 wrote Baker, \u0022the government will be out the money, not Moderna.\u0022Despite the fact that Moderna\u0026#039;s price tag for its coronavirus vaccine is the highest yet announced by any corporation involved with Operation Warp Speed, Moderna CEO Stéphane Bancel on Wednesday characterized the cost as a discount during a conference call announcing the company\u0026#039;s massive second-quarter revenue increase.But Public Citizen noted the absurdity of charging the public anything at all for a vaccine developed entirely with taxpayer funding.\u0022They want us to buy back a vaccine developed with our tax dollars,\u0022 the group tweeted.